Johnson & Johnson changes 340B pricing, requiring disproportionate share hospitals to pay full price for Stelara and Xarelto, with critics claiming it violates federal law and increases hospital costs.
Johnson & Johnson (J&J) will implement a new policy for 340B pricing on October 15, requiring disproportionate share hospitals to purchase drugs Stelara and Xarelto at full price and submit data for a rebate. Critics, including the 340B Health hospital lobby and HRSA, claim this move violates federal law and increases costs for hospitals, possibly leading to closures for safety-net facilities. J&J defends the change as an effort to improve the 340B program's integrity.
7 months ago
17 Articles
Articles
This is your last free story for the month. Don’t miss out — Subscribe now for unlimited access!